[1] |
Wu J, You J, Wang S , et al. Insights into the activation and inhibition of angiotensin Ⅱ type 1 receptor in the mechanically loaded heart[J]. Circ J, 2014,78(6):1283-1289.
doi: 10.1253/circj.CJ-14-0470
|
[2] |
Te Riet L, Van Esch J H, Roks A J, et al. Hypertension: renin-angiotensin-aldosterone system alterations[J]. Circ Res, 2015,116(6):960-975.
doi: 10.1161/CIRCRESAHA.116.303587
pmid: 25767283
|
[3] |
Toischer K, Rokita A G, Unsold B , et al. Differential cardiac remodeling in preload versus after load[J]. Circulation, 2010,122(10):993-1003.
doi: 10.1161/CIRCULATIONAHA.110.943431
pmid: 20733099
|
[4] |
Davis J, Davis L C, Correll R N , et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy[J]. Cell, 2016,165(5):1147-1159.
doi: 10.1016/j.cell.2016.04.002
pmid: 27114035
|
[5] |
Olsen N T, Dimaano V L, Fritz-Hansen T , et al. Hypertrophy signaling pathways in experimental chronic aortic regurgitation[J]. J Cardiovasc Transl Res, 2013,6(5):852-860.
doi: 10.1007/s12265-013-9503-y
pmid: 23888404
|
[6] |
Bartelds B, Borgdorff M A, Smit-Van Oosten A, et al. Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load[J]. Eur J Heart Fail, 2011,13(12):1275-1282.
doi: 10.1093/eurjhf/hfr134
|
[7] |
Bonow R O, Carabello B A, Chatterjee K , et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. Circulation, 2008,118(15):e523-e661.
doi: 10.1161/CIRCULATIONAHA.108.190748
pmid: 18820172
|
[8] |
Ago T, Yang Y, Zhai P , et al. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload[J]. J Cardiovasc Transl Res, 2010,3(4):304-313.
doi: 10.1007/s12265-010-9182-x
pmid: 20559781
|
[9] |
Plante E, Lachance D, Beaudoin J , et al. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation[J]. Circ Heart Fail, 2009,2(1):25-32.
doi: 10.1161/CIRCHEARTFAILURE.108.801548
pmid: 19808312
|
[10] |
You J, Wu J, Zhang Q , et al. Differential cardiac hypertrophy and signaling pathways in pressure versus volume overload[J]. Am J Physiol Heart Circ Physiol, 2018,314(3):H552-H562.
doi: 10.1152/ajpheart.00212.2017
pmid: 29196344
|
[11] |
Bers D M . Cardiac excitation-contraction coupling[J]. Nature, 2002,415(6868):198-205.
doi: 10.1038/415198a
pmid: 11805843
|
[12] |
Zou Y, Liang Y, Gong H , et al. Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy[J]. Hypertension, 2011,58(6):1099-1110.
doi: 10.1161/HYPERTENSIONAHA.111.173500
pmid: 21986507
|
[13] |
Zhang T, Maier L S, Dalton N D , et al. The deltaC isoform of CaMKⅡ is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure[J]. Circ Res, 2003,92(8):912-919.
doi: 10.1161/01.RES.0000069686.31472.C5
pmid: 12676814
|
[14] |
Zhang T, Zhang Y, Cui M , et al. CaMKⅡ is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis[J]. Nat Med, 2016, DOI: 10.1038/nm.4017.
doi: 10.1038/s41591-019-0665-2
pmid: 31792462
|
[15] |
Suetomi T, Willeford A, Brand C S , et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca$^{2+}$/calmodulin-dependent protein kinase Ⅱ delta signaling in cardiomyocytes are essential for adverse cardiac remodeling[J]. Circulation, 2018,138(22):2530-2544.
doi: 10.1161/CIRCULATIONAHA.118.034621
pmid: 30571348
|
[16] |
Sussman M A, Volkers M, Fischer K , et al. Myocardial AKT: the omnipresent nexus[J]. Physiol Rev, 2011,91(3):1023-1070.
doi: 10.1152/physrev.00024.2010
|
[17] |
Moc C, Taylor A E, Chesini G P , et al. Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy[J]. Cardiovasc Res, 2015,105(2):160-170.
doi: 10.1093/cvr/cvu243
pmid: 25411382
|
[18] |
Beltowski J . Leptin and the regulation of endothelial function in physiological and pathological conditions[J]. Clin Exp Pharmacol Physiol, 2012,39(2):168-178.
doi: 10.1111/j.1440-1681.2011.05623.x
pmid: 21973116
|
[19] |
Bernardo B C, Weeks K L, Pretorius L , et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies[J]. Pharmacol Ther, 2010,128(1):191-227.
doi: 10.1016/j.pharmthera.2010.04.005
pmid: 20438756
|
[20] |
Wende A R, O'Neill B T, Bugger H, et al. Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes[J]. Mol Cell Biol, 2015,35(5):831-846.
doi: 10.1128/MCB.01109-14
pmid: 25535334
|